Evaluating Cognition in Parkinson’s Disease Clinical Trials: Key Considerations for Study Design and Conduct, New Webinar Hosted by Xtalks
TORONTO (PRWEB) March 04, 2019 -- The past two decades have seen multiple industry trials explore the impact of drug treatments (primarily dopaminergic therapies and cholinesterase inhibitors) on cognition in PD and PD dementia (PDD). This activity resulted in the approval of rivastigmine for PDD in 2007 but has not resulted in any further approvals or in labelling for cognition endpoints. And with respect to cognition, the focus for industry trials has remained on secondary or exploratory outcomes in idiopathic PD, or primary outcomes in PDD. In recent years, three important efforts have begun to alter planned clinical development programs in important ways:
• Diagnostic criteria for Mild Cognitive Impairment in PD (PD-MCI), published in 2012
• The FDA Parkinson’s Disease “Voice of the Patient” meeting, held in 2015
• Development of potentially disease-modifying therapies (DMTs), especially those targeted at α-synuclein (e.g. Prasinezumab (RO7046015/PRX002)) Phase II, ongoing
Given these efforts, it is clear that the symptoms of cognitive impairment in people with PD are considered significant.
Join industry experts from Cogstate in a live session on Tuesday, March 19, 2019 at 11am EDT (3pm GMT) to learn about:
• Important trial design considerations for measuring cognition in Parkinson’s disease
• Identifying and characterizing suitable trial populations
• Selection of cognitive clinical outcomes assessments
Featured speakers include:
• Eric Siemers, Distinguished Medical Adviser
• Chris Edgar, Senior Vice President, Clinical Science
• Lisle Kingery, Clinical Science Director
• Paul Maruff, Chief Science Officer
For more information or to register for this event, visit Evaluating Cognition in Parkinson’s Disease Clinical Trials: Key Considerations for Study Design and Conduct.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Candice Tang, Xtalks, http://www.xtalks.com, 4169776555, [email protected]
Share this article